AndrewDZelenetzMDPhD

PubMed

• Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma.
  Pallawi Torka, Tatyana Feldman, Kerry J Savage, Nivetha Ganesan, Esther Drill
  Journal of Clinical Oncology. 2024-12-11
• A phase 1 trial of abexinostat with ibrutinib in relapsed/refractory mantle cell lymphoma and non-germinal center diffuse large B cell lymphoma.
  Ashwath Gurumurthi, Kurt S Bantilan, Paul A Hamlin, Anita Kumar, Matthew Matasar
  Leukemia & Lymphoma. 2024-12-01
• Severe toxicity, but long-term persistence of CAR T cells after immune checkpoint inhibitors in large B-cell lymphoma.
  Xavier Deschênes-Simard, Martina Pennisi, Miguel-Angel Perales, Gunjan L Shah, Andrew D Zelenetz
  Leukemia & Lymphoma. 2024-11-20

Journal Articles

• Venetoclax plus R- or G-CHOP in Non-Hodgkin Lymphoma: Results from the CAVALLI Phase 1b Trial  
  Andrew D Zelenetz, Andre Goy, Mehrdad Mobasher, Carla Casulo, Blood
• Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic Leukemia  
  Vincent Miller, Tariq Mughal, Nicole Lamanna, Andrew Zelenetz, Mark L Heaney, Mark G Frattini, Nature
• Real World Outcomes and Management Strategies for Venetoclax-Treated Chronic Lymphocytic Leukemia Patients in the United States  
  Arun K Singavi, Andrew Zelenetz, Nicole Lamanna, Bruce D Cheson, Richard R Furman, Jakub Svoboda, Stephen J Schuster, John N Allan, Chaitra S Ujjani, Haematologica
• Maintaining the dose intensity of ICE chemotherapy with a thrombopoietic agent, PEG-rHuMGDF, may confer a survival advantage in relapsed and refractory aggressive non-...  
  Moskowitz CM, Hamlin PA, Gabrilove J, Bertino J, Portlock C, Straus D, Gencarelli A, Nimer S, Zelenetz AD, Ann Oncol 2007 Nov;18(11):1842-50
• NCCN: Non-Hodgkin's lymphoma.  
  Zelenetz AD. and R. T. Hoppe, Cancer Control 2001, 8:102-13
• Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin lymphoma: CALGB 59804.  
  Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, Zelenetz AD, Cheson BD, Canellos GP; Cancer Leukemia Group B, Ann Oncol 2007 Jun; 18(6):1071-9
• Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine.  
  Advani R, Horwitz S, Zelenetz AD, Horning SJ, Leuk Lymphoma. 2007 Mar; 48(3):521
• Molecular cytogenetic analysis of follicular lymphoma (FL) provides detailed characterization of chromosomal instability associated with the t(14;18)(q32;q21) positive...  
  Nanjangud G, Rao PH, Tenuya-Feldstein J, Donnelly G, Qin J, Mehra S, Jhanwar SC, Zelenetz AD, Chaganti RS, Cytogenet Genome: Res 2007;118(2-4):337-44
• Automated matching and segmentation of lymphoma on serial CT examinations.  
  Yan J, Zhao B, Curran S, Zelenetz AD, Schwartz LH, Med. Phys. 2007 34(1):55-62
• Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: a retrospective analysis of a uniformly-tre...  
  Liedtke M, Hamlin PA, Moskowitz CH, Zelenetz AD, Ann Oncol. 2006 Jun;17(6):909-13. Epub 2006 May 3
• Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma.  
  Kewalramani, TK, Zelenetz AD, Teruya-Feldstein J, Hamlin PA, Yahalom J, Horwitz SH, Nimer SD, Moskowitz CH, Br J Haematol. 2006 134(2):202-7
• Hodgkin’s disease/lymphoma. Clinical practice guidelines in oncology.  
  Hoppe RT, Advani RH, Biernan PJ, Bloomfield CD, Buadi F, Djulgegovic B, Forero A, Gordon LI, Hernandez-Ilizaliturri FJ, Kaminski MS, Love G, Maloney DG, Mauch PM, Moor..., J Natl Compr Canc Netw 2006 Mar 4(3): 210-30
• Non-Hodgkin’s lymphoma: Clinical practice guidelines in oncology.  
  Zelenetz AD, Advani RH, Buadi F, Cabanillas F, Caligiuri MA, Czuczman MS, Damon LE, Fayad L, Flinn IW, Forero A, Glenn MJ, Gockerman JP, Gordon LI, Harris NL, Hoppe RT..., J Natl Compr Canc Netw 2006 Mar 4(3): 258-310
• Primary mediastinal large B cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to ...  
  Hamlin PA, Portlock CS, Straus DJ, Noy A, Singer A, Horwitz SM, O’Connor OA, Yahalom J, Zelenetz AD, Moskowitz CH, Br J Haematol 2005 Sep; 130(5):691-9
• Phase II clinical experience with the novel proteasome inhibitor Bortezomib in patients with indolent non-Hodgkin’s lymphoma and mantle cell lymphoma.  
  O’Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J,..., J Clin Oncol 2005: 676-684
• R-CHOP-14 in patients with diffuse large B-Cell lymphoma (DLBCL): Feasibility and Preliminary Efficacy.  
  Halaas JL, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, O’Connor OA, Yahalom J, Zelenetz AD, Leukemia and Lymphoma 2005, 46(4): 541-547
• The radioisotope contributes significantly to the activity of radioimmunotherapy.  
  Davis TA, Kaminsky MS, Leonard JP, Hsu FJ, Wilkinson M, Zelenetz AD, Wahl RL, Kroll S, Coleman M, Goris M, Levy R, Knox SI, Clin Cancer Res 2004 Dec; 1:10(23):7792-8
• Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B cell lymphomas.  
  Houldsworth J, Olshen AB, Cattoretti G, Donnelly GB, Teruya-Feldstein J, Qin J, Palanisamy N, Shen Y, Dyomina K, Petlakh M, Pan Q, Zelenetz AD, Dalla-Favera R, Chagant..., Blood 2004 103(5): 1862-68
• The NHL-15 protocol for aggressive non-Hodgkin's lymphomas: a sequential dose-dense, dose-intense regimen of doxorubicin, vincristine and high-dose cyclophosphamide.  
  Portlock CS, Qin J, Schaindlin P, Roistacher N, Myers J, Filippa D, Louie D, Zelenetz AD, O'Brien JP, Moskowitz C, Norton L, Yahalom J, Straus DJ, Bertino JR, Ann Oncol 2004 15(10): 1495-503
• Adverse Prognostic Significance of CD 20 Positive Reed-Sternberg Cells in Classical Hodgkin’s Disease.  
  Portlock CS, Donnelly GB, Qin J, Straus D, Yahalom J, Zelenetz AD, Noy A, O’Connor O, Horwitz S, Moskowitz CH, Filippa DA, British Journal of Hematology British Journal of Hematology, 2004 Jun;125(6):701-8
• Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease.  
  Moskowitz CH., Kewalramani T, Nime SD, Gonzalez M, Zelenetz AD, Yahalom J, Br J Haematol 2004, 124(5): 645-52
• Progressive disease following autologous transplantation in patients with chemosensitive relapsed or primary refractory Hodgkin's disease or aggressive non-Hodgkin's l...  
  Kewalramani T, Nimer SD, Zelenetz AD, Malhotra S, Qin J, Yahalom J, Moskowitz CH, Bone Marrow Transplantation 2003, 32(7):673-9
• Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem cell rescue in patients with newly diagnosed primary CNS lymphoma: An int...  
  Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz AD, Nimer SD, DeAngelis LM, Journal of Clinical Oncology 2003, 21(22):4151-56
• Activity of a novel anti-folate (PDX, 10-propargyl 10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene express...  
  Wang ES, O'Connor O, She T, Zelenetz AD, Sirotnak A, Moore MAS, Leukemia and Lymphoma 2003, 44:1027-1035
• Vaccination with CD20 peptides includes a biologically active, specific immune response in mice.  
  Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz AD, Scheinberg DA, Blood 2002, 99(10):3748-55
• Join now to see all

Books/Book Chapters

• Methods of Enzymology. 
  Chapter: Efficient construction of complex directional cDNA libraries in a SfiI cassette 
  Page 517 - 530Zelenetz ADEditors: Wu R.Academic Press Inc, San Diego, CA
• The Non-Hodgkin’s Lymphomas. 
  Chapter: The pathogenesis of the low grade B-cell lymphomas 
  Zelenetz AD, Brodeur DEditors: Magrath, I.Edward Arnold, Kent, United KingdomEdition 2,
• Oncology. 
  Chapter: The non-Hodgkin’s Lymphomas – An Evidence Based Approach 
  Zelenetz, A.D., Horwitz S.MEditors: Chang, A.E., Ganz P.A., Hayes, D.F., Kinsella T., Pass, H.I., Schiller, J.H., Stone, R.M., Strecher.
• Mechanism of B Cell Neoplasia. 
  Page 359 - 369Zelenetz ADEditors: Melchers, F and Potter M.Editiones Roche, Basel, Switzerland
• Join now to see all

Abstracts/Posters

• Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Veneto-STOP Study: Sequential Assessment of Minimal Residual Disease By Next Generation Sequencing to Optimize Outcomes and Minimize Exposure in Venetoclax-Treated CLL...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• A Phase II, Multicenter Study of High Dose Chemotherapy with Autologous Stem Cell Transplant Followed By Maintenance Therapy with Romidepsin for T-Cell Lymphoma
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Time to Second Treatment As a Proxy for Overall Survival in CLL/SLL: Identifying Risk Factors to Help Guide Treatment Selection
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Expectant Management of Extranodal Marginal Zone Lymphoma of Bronchial-Associated Lymphoid Tissue (BALT)
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Evolution in Practice Patterns and Differences Among Experts and Community Healthcare Providers in the Treatment of Patients with Chronic Lymphocytic Leukemia
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of ...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Long-Term Follow-up Confirms Durability of Single-Agent Brentuximab Vedotin As Pre-Transplant Salvage for Classical Hodgkin Lymphoma
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Genomic Profiling of Mantle Cell Lymphoma Suggests Poor-Risk Profile Is Present at Diagnosis and Does Not Arise By Tumor Evolution
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Contemporary Outcomes in HTLV-1-Associated Adult T-Cell Leukemia/Lymphoma: Single-Institution Experience
  Andrew D. Zelenetz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Join now to see all

Lectures

• Results of the PI3Kδ inhibitor ME-401 alone or with rituximab in relapsed/refractory (R/R) follicular lymphoma (FL). 
  ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019
• 17th International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas and Myeloma® 
  Physicians' Education Resource, LLC, New York, New York - 2/15/2013